Results 181 to 190 of about 4,210,891 (389)

Conflicting recommendations: A labyrinth for the clinician and patients: A comment to Eisenberg's et al. “medical cannabis for chronic pain” [PDF]

, 2022
Koen Van Boxem, A. van der Gaag, Monique A. H. Steegers, Jan Willem Kallewaard, André Wolff, Kris Vissers, Jan Van Zundert   +6 more
openalex   +1 more source

Association of fully branded, standardized packaging and limited flavor and brand descriptors of e‐liquids with interest in trying products among youths in Great Britain

Addiction, Volume 120, Issue 4, Page 620-628, April 2025.
Abstract Background and aims Many vaping products feature bright colors and novel brand names and flavor descriptors, which may appeal to youth. We measured the strength of the associations between e‐liquid packaging design (branded, white standardized or white standardized limiting brand and flavor descriptors) and perceived peer interest in trying ...
Eve Taylor, Erikas Simonavičius, Matilda Nottage, Ann McNeill, Deborah Arnott, Hazel Cheeseman, David Hammond, Jessica Reid, Pete Driezen, Kimberly D'Mello, Katherine East   +10 more
wiley   +1 more source

Cannabinoid hyperemesis syndrome: an underreported entity causing nausea and vomiting of pregnancy [PDF]

, 2018
Introduction: In the western world, cannabis is the most widely used drug of abuse. Cannabinoid hyperemesis syndrome, which seems to be a rare paradoxical reaction in individuals with a particular predisposition, is characterized by cyclic severe nausea ...
Güth, Uwe, Huang, Dorothy, Jürgens, Frank, Lapaire, Olav, Schmid, Seraina   +4 more
core  

Medical cannabis for chronic pain [PDF]

BMJ, 2021
Edeltraut, Kröger, Clermont E, Dionne
openaire   +2 more sources

Changing trends in drug overdose mortality in Spain, 2001–2022

Addiction, EarlyView.
Abstract Aim To measure the evolution of drug overdose mortality in Spain between 2001 and 2022. Design, Setting, Participants A repeated cross‐sectional observational study using nationwide mortality data from Spain, 2001–2022, among individuals aged 15–64 years.
Florencia Giné, Marta Donat, Juan Miguel Guerras, Gregorio Barrio, María José Belza, Julieta Politi, Enrique Regidor   +6 more
wiley   +1 more source

Educating Patients on Cannabidiol (CBD) [PDF]

, 2019
As the popularity of cannabidiol (CBD) increases, more patients are interested in trying a natural adjunct to more standard medications. But with no current FDA oversight, an estimated 70% of CBD products could be mislabeled.
Pratt, Catherine G
core   +1 more source

Concerns of Patients With Cancer on Accessing Cannabis Products in a State With Restrictive Medical Marijuana Laws: A Survey Study [PDF]

, 2019
Vinita Singh, Ali John Zarrabi, Kimberly Curseen, Roman M. Sniecinski, Justine W. Welsh, Anne Marie McKenzie-Brown, Wendy Baer, Theresa Gillespie   +7 more
openalex   +1 more source

Interventions to change vaping harm perceptions and associations between harm perceptions and vaping and smoking behaviours: A systematic review

Addiction, EarlyView.
Abstract Aims To synthesize and describe the evidence from among young people and adults to assess: (i) what interventions have been effective in changing vaping harm perceptions; and (ii) to what extent vaping harm perceptions predict any changes in vaping and smoking behaviours.
Katherine East, Erikas Simonavičius, Eve V. Taylor, Leonie Brose, Deborah Robson, Ann McNeill   +5 more
wiley   +1 more source

A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania [PDF]

, 2023
Emily Hajjar, Allison Herens, Erin L. Kelly, Kayla Madden, Jessica M. Lungen, Brooke Worster   +5 more
openalex   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source